RxStrategies, Inc.

Clinical Insights: April 30, 2020

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Ongentys® (opicapone) Capsules – New Drug Approval – April 27, 2020 – Neurocrine Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral…

Read More...

Clinical Insights: April 24, 2020

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval TukysaTM (tucatinib) – New Drug Approval – April 17, 2020 – As part of Project Orbis, the U.S. Food and Drug Administration approved TukysaTM (tucatinib) in combination with chemotherapy…

Read More...

Clinical Insights: April 16, 2020

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Koselugo® (selumetinib) – New Drug Approval – April 10, 2020 – The U.S. Food and Drug Administration approved Koselugo® (selumetinib) for the treatment of pediatric patients, 2 years…

Read More...

Clinical Insights: April 9, 2020

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Sevenfact® (coagulation factor VIIa [recombinant]-jncw) – New Drug Approval – April 1, 2020 – The U.S. Food and Drug Administration approved Sevenfact® [coagulation factor VIIa (recombinant)-jncw] for the treatment and…

Read More...

Clinical Insights: April 1, 2020

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Zeposia® (ozanimod) Capsules – New Drug Approval – March 26, 2020 – Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Zeposia® (ozanimod) 0.92…

Read More...

Clinical Insights: March 24, 2020

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Isturisa® (osilodrostat) Tablets – New Orphan Drug Approval – March 6, 2020 – The U.S. Food and Drug Administration announced the approval of Isturisa® (osilodrostat)…

Read More...

Connect with RxStrategies at the 340B Coalition Winter Conference

The 2020 340B Coalition Winter Conference is near! RxStrategies is a proud Pinnacle Level sponsor of this great event, where attendees will receive the latest actionable intelligence in areas such as 340B implementation and operations, compliance, contract pharmacy, inventory management, and specialty pharmacy. The conference will take place in San Diego, CA, February 10 –…

Read More...

Happy Holidays!

  Happy Holidays from the RxStrategies team! Wishing you a time filled with fun and joy. Best wishes for the New Year!   Warm Regards, The RxStrategies Team

Read More...

Connect With RxStrategies at the ASHP Midyear Clinical Meeting & Exhibition

RxStrategies will be an exhibitor at the ASHP Midyear Clinical Meeting & Exhibition in Las Vegas, NV, December 8 – 12. As the world’s largest gathering of pharmacy professionals, ASHP Midyear provides a space for conversation, learning, and networking for all attendees.   Skip Devanny, Rhodie Smith, Jonathan Ghenn and Justin Rolling will be representing…

Read More...

Connect with RxStrategies at the 2019 Fall Hospital Pharmacy Conference

RxStrategies will be at the Fall Hospital Pharmacy (HCP) Conference on October 28-30 in Kansas City, MO. Team members Justin Rolling and Rhodie Smith will be networking with peers, attending educational sessions and sharing their expertise in 340B solutions. Learn more about the conference here.   Contact us to connect during the conference and learn…

Read More...

Let’s Connect: 2019 NWRPCA/CHAMPS Fall Primary Care Conference

RxStrategies’ Todd Hudnall and Krista Scanlon will attend the 2019 NWRPCA/CHAMPS Fall Primary Care Conference in Seattle. The conference takes place October 5 – 8, and provides education and training, information and resource sharing, coalition building, and program and policy development for like-minded community health professionals and their partners. Learn more about the event here….

Read More...

Clinical Insights: September 30, 2019

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Jynneos™ (smallpox and monkeypox vaccine, live, nonreplicating) – New Vaccine Approval – September 24, 2019 – The U.S. Food and Drug Administration announced the approval…

Read More...